万泰生物（603392）(603392.SH)公告，公司全资子公司厦门万泰沧海生物技术有限公司收到国家药品 监督管理局(简称"国家药监局")行政许可文书《受理通知书》，公司申报的"重组呼吸道合胞病毒疫苗 (CHO细胞)"临床试验申请已获得受理。 ...

每经AI快讯，12月17日，万泰生物（603392）(603392.SH)公告称，公司全资子公司厦门万泰沧海生物 技术有限公司收到国家药监局行政许可文书《受理通知书》，公司申报的"重组呼吸道合胞病毒疫苗 (CHO细胞)"临床试验申请已获得受理。该疫苗由厦门大学、厦门万泰沧海生物技术有限公司联合研 制，采用基因工程重组技术、以CHOZN细胞生产。若该产品研发成功上市，将丰富公司产品布局，提 高市场竞争力。但药品从研制到上市面临诸多环节，过程周期长，后续能否获得批准进行临床试验并顺 利推进存在不确定性。该产品获得临床试验申请受理通知书，对公司近期业绩不会产生显著影响。 ...

万泰生物12月17公告，近日，公司全资子公司厦门万泰沧海生物技术有限公司收到国家药品监督管理局 行政许可文书《受理通知书》，公司申报的"重组呼吸道合胞病毒疫苗（CHO细胞）"临床试验申请已获 得受理。此次重组呼吸道合胞病毒疫苗（CHO细胞）临床试验申请的受理，是公司创新疫苗研发过程 中的重要一步，标志着公司基于自主技术平台的重组蛋白疫苗研发战略取得关键进展，若该产品研发未 来成功上市，将有利于丰富公司产品布局，进一步提高公司市场竞争力。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 北京万泰生物药业股份有限公司（以下简称"公司"）本次注销回购专用证券账户中已回购但尚未使用 的729,970股股份，本次注销完成后，公司总股本将由1,265,122,774股减少至1,264,392,804股。 ● 股份注销日：2025年12月17日 一、回购股份方案及实施情况 2022年8月5日，公司召开第五届董事会第十三次会议、第五届监事会第十三次会议，审议通过了《关于 以集中竞价交易方式回购公司股份方案的议案》，同意公司使用自有资金以集中竞价交易方式回购股份 用于员工持股计划或股权激励。具体内容详见公司于2022年8月6日、2022年8月13日在指定信息披露媒 体披露的《北京万泰生物药业股份有限公司关于以集中竞价交易方式回购公司股份方案的公告》（公告 编号：2022-070）、《北京万泰生物药业股份有限公司关于以集中竞价交易方式回购公司股份的回购报 告书》（公告编号：2022-072）。 2022年12月 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603392 证券简称：万泰生物 公告编号：2025-064 2022年8月5日，公司召开第五届董事会第十三次会议、第五届监事会第十三次会议，审议通过了《关于 以集中竞价交易方式回购公司股份方案的议案》，同意公司使用自有资金以集中竞价交易方式回购股份 用于员工持股计划或股权激励。具体内容详见公司于2022年8月6日、2022年8月13日在指定信息披露媒 体披露的《北京万泰生物药业股份有限公司关于以集中竞价交易方式回购公司股份方案的公告》（公告 编号：2022-070）、《北京万泰生物药业股份有限公司关于以集中竞价交易方式回购公司股份的回购报 告书》（公告编号：2022-072）。 2022年12月21日，公司完成回购，已通过集中竞价交易方式累计回购股份1,585,320股，占回购完成时公 司总股本的0.1750%，存放于公司开立的回购专用证券账户。具体内容详见公司于2022年12月23日在指 定信息披露媒体披露的《北京万泰生物药业股份有限公司关于股份回购实施结果暨股份变动公告》（公 告编号：2022-103）。 二、回购股份的使用情况 北京万泰生物药 ...

证券代码：603392 证券简称：万泰生物 公告编号：2025-064 北京万泰生物药业股份有限公司 关于实施回购股份注销暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2022年12月21日，公司完成回购，已通过集中竞价交易方式累计回购股份1,585,320 股，占回购完成时公司总股本的0.1750%，存放于公司开立的回购专用证券账户。具体内 容详见公司于2022年12月23日在指定信息披露媒体披露的《北京万泰生物药业股份有限 公司关于股份回购实施结果暨股份变动公告》（公告编号：2022-103）。 二、回购股份的使用情况 2023年3月9日，公司召开第五届董事会第十八次会议、第五届监事会第十八次会议， 并于2023年3月27日召开2023年第二次临时股东大会，审议通过了《关于<北京万泰生物 药业股份有限公司2023年员工持股计划（草案）>及其摘要的议案》等相关议案。具体内 容详见公司于2023年3月10日、2023年3月28日在上海证券交易所网站（www.sse.com.cn） 及指定信息 ...

Group 1 - The central economic work conference has outlined the overall requirements, policy orientation, and key tasks for the upcoming "15th Five-Year Plan" period, emphasizing the need to expand domestic demand, optimize supply, and develop new productive forces tailored to local conditions [1] - The "Central Finance Annual Dialogue 2025" held in Beijing gathered nearly 300 representatives from various sectors to discuss building a modern industrial system and strengthening the foundation of the real economy [1] Group 2 - Experts highlighted that the cultivation of new productive forces relies on innovative breakthroughs in capital models, including the organic combination of limited and unlimited liability, and the optimization of capital flow under the registration system [2] - Service consumption is identified as a new productive force for expanding domestic demand, with examples showing how digitalization and intelligent upgrades can enhance operational efficiency and drive consumer spending [2] Group 3 - The cybersecurity sector is recognized as a "golden track" for the "15th Five-Year Plan," with the integration of AI into production systems transforming cybersecurity from a cost item to a value item, characterized by stability, breadth, and strength [3] - The importance of green development, industrial transformation, and health inclusivity was discussed, with examples of how technological innovation can convert environmental investments into economic benefits [4] Group 4 - In the health industry dialogue, breakthroughs in the development of domestic HPV vaccines were shared, emphasizing the need for continuous technological innovation in major disease prevention systems [5] - The consumer market is evolving towards quality, personalization, and experiential consumption, with traditional brands needing to embrace younger consumers through service upgrades and product innovation [6][7]

Group 1 - The event "Central Radio and Television Finance Annual Dialogue 2025" focuses on the theme "Setting Sail for the 14th Five-Year Plan with New Momentum" to gather insights and build connections among government, industry, academia, and finance [1][3] - Approximately 300 representatives from various sectors participated, discussing the construction of a modern industrial system and strengthening the foundation of the real economy [1][3] - The dialogue aims to enhance industrial collaboration and address challenges while promoting economic stability and growth [3] Group 2 - Former Vice Chairman of the National Social Security Fund Wang Zhongmin highlighted that the registration system has significantly boosted the prosperity of China's capital market, which will further facilitate the cultivation of new productive forces during the 14th Five-Year Plan [4] - Former Vice Minister of Commerce Wei Jianguo emphasized that service consumption will play a crucial role in expanding domestic demand and will be a key strategy for economic recovery [5] - Tsinghua University’s Professor He Ping stated that a stable and efficient financial system is essential for supporting technological innovation and addressing related challenges [6] Group 3 - Shenyin Wanguo Securities' Chairman Zhou Haichen discussed four new requirements for the capital market during the 14th Five-Year Plan: serving new productive forces, managing household wealth, building a strong financial nation, and achieving high-level financial openness [8] - Former Deputy Secretary-General of the National Development and Reform Commission Fan Hengshan stressed the importance of understanding the relationship between the development of new productive forces and strategic requirements, development measures, and environmental factors [10] - Shenzhen Stock Exchange's Vice General Manager Li Mingzhong expressed the need for a positive interaction among regulation, market, and media to create a conducive environment for capital market development [12] Group 4 - Shanghai Jiao Tong University’s Chairman Tu Guangshao pointed out that financial services must evolve to keep pace with changes in the real economy and new forms of development [14] - The dialogue included discussions on green development, industrial transformation, and health service optimization, emphasizing the importance of these areas for new productive force cultivation [16] - The session on advanced manufacturing transformation focused on digital energy innovation and the integration of intelligent technologies, outlining practical paths and opportunities for development [18] Group 5 - The dialogue on the big health industry innovation highlighted discussions on vaccine research, immune management, and smart health hardware applications, contributing to the construction of a healthy China [20] - A report on county-level credit construction and high-quality development was released, providing theoretical support and practical guidance for local economic development [21] - The collaboration between Shenzhen Stock Exchange and Central Radio and Television Network aims to enhance the multi-layered bond market and support the development of new productive forces [24]

Core Viewpoint - Wanta Biotech announced the postponement of the "Phase II Expansion Project for the Nine-Valent Cervical Cancer Vaccine" to December 2026, without changing the implementation subject, location, or investment scale [2] Group 1 - The sixth board meeting of Wanta Biotech will be held on December 12, 2025, to review the proposal for the project delay [2] - The proposal does not involve any changes to the use of raised funds and does not require shareholder approval [2]

Core Viewpoint - Wanta Bio announced the postponement of the "Phase II Expansion Project for the Nine-Valent Cervical Cancer Vaccine" to December 2026, without changes to the implementation entity, location, or investment scale [1] Group 1 - The company's board of directors approved the proposal to delay the project [1] - The postponement does not involve any changes to the use of raised funds [1] - There is no need to submit the proposal for shareholder meeting approval [1]